Bechan Sharma
The authorities of Chinese authoritoies declared a pneumonia outbreak by an unknown virus at Wuhan of Hubei Province during December 2019,. The publication of the genomic sequence of a novel coronavirus (nCoV), the global scientific community jumped into conducting research on varied aspects of this function with great interest. This nCoV or 2019-nCoV was finally renamed as Severe Acute Respiratory Syndrome Corona Virus Type 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses. The SARS-CoV-2 belongs to the family: Coronaviridae, genus: Beta coronavirus , and subgenus : Sarbecovirus. This virus enters the human body through mouth, eye and nose. Finally, it reaches into the lung cells via binding of the S1 domain of spike protein with a host cell surface enzyme, angiotensin converting enzyme type 2 (ACE2) receptor. The entry process of this virus is facilitated by the serine protease TMPRSS2 for S protein priming. It has been observed that a TMPRSS2 inhibitor which has been approved for the clinical use can block the entry. Hence, it can serve as a potential therapeutic target and drug development. The SARS-CoV-2 has a positive single strand of RNA with genome size of 29.8 Kb encoding for 29 proteins using 3 open reading frames. After infecting the lung cells, it develops the disease, CoVID19. I would present an update about the structure and function of SARS CoV2, the diagnostic tools, antiCoVID19 agents and the therapeutic targets to combat CoVID19.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi